Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA

被引：1
|
作者：
Dickler, M. N.
Saura, C.
Oliveira, M.
Richards, D. A.
Krop, I. E.
Cervantes, A.
Stout, T. J.
Jin, H.
Savage, H. M.
Wilson, T. R.
Baselga, J.
机构：
[1] Mem Sloan Kettering Canc Ctr, Mem Hosp, 1275 York Ave, New York, NY 10021 USA
[2] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol, Barcelona, Spain
[3] US Oncol Res, The Woodlands, TX USA
[4] Dana Farber Canc Inst, Boston, MA USA
[5] Univ Valencia, Inst Hlth Res INCLIVA, Valencia, Spain
[6] Genentech Inc, San Francisco, CA 94080 USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P6-12-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-12-01
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
    Dickler, Maura N.
    Saura, Cristina
    Richards, Donald A.
    Krop, Ian E.
    Cervantes, Andres
    Bedard, Philippe L.
    Patel, Manish R.
    Pusztai, Lajos
    Oliveira, Mafalda
    Cardenas, Alison K.
    Cui, Na
    Wilson, Timothy R.
    Stout, Thomas J.
    Wei, Michael C.
    Hsu, Jerry Y.
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2018, 24 (18) : 4380 - 4387
  • [2] A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor positive (HR plus ) advanced breast cancer (BC).
    Dickler, Maura N.
    Saura, Cristina
    Richards, Donald A.
    Krop, Ian E.
    Cervantes, Andres
    Bedard, Philippe L.
    Patel, Manish R.
    Pusztai, Lajos
    Oliveira, Mafalda
    Ware, Joseph A.
    Jin, Huan
    Wilson, Timothy R.
    Stout, Thomas
    Wei, Michael C.
    Hsu, Jerry Y.
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors
    Baselga, J.
    Cortes, J.
    De Laurentiis, M.
    Dieras, V.
    Harbeck, N.
    Hsu, J.
    Jin, H.
    Schimmoller, F.
    Wilson, T. R.
    Im, Y-H
    Jacot, W.
    Krop, I. E.
    Verma, S.
    CANCER RESEARCH, 2016, 76
  • [4] SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors
    Baselga, J.
    Cortes, J.
    De laurentiis, M.
    Dent, S.
    Dieras, V.
    Harbeck, N.
    Hsu, J.
    Jin, H.
    Schimmoller, F.
    Wilson, T. R.
    Im, Y-H
    Jacot, W.
    Krop, I. E.
    Verma, S.
    CANCER RESEARCH, 2017, 77
  • [5] ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis
    Urso, Loredana
    Vernaci, Grazia
    Carlet, Jessica
    Lo Mele, Marcello
    Fassan, Matteo
    Zulato, Elisabetta
    Faggioni, Giovanni
    Menichetti, Alice
    Di Liso, Elisabetta
    Griguolo, Gaia
    Falci, Cristina
    Conte, Pierfranco
    Indraccolo, Stefano
    Guarneri, Valentina
    Dieci, Maria Vittoria
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [6] Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
    Dent, S.
    Cortes, J.
    Im, Y-H
    Dieras, V
    Harbeck, N.
    Krop, I. E.
    Wilson, T. R.
    Cui, N.
    Schimmoller, F.
    Hsu, J. Y.
    He, J.
    De Laurentiis, M.
    Sousa, S.
    Drullinsky, P.
    Jacot, W.
    ANNALS OF ONCOLOGY, 2021, 32 (02) : 197 - 207
  • [7] The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Grinshpun, Albert
    Sandusky, Zachary M.
    Jeselsohn, Rinath
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 169 - 181
  • [8] PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Fusco, Nicola
    Malapelle, Umberto
    Fassan, Matteo
    Marchio, Caterina
    Buglioni, Simonetta
    Zupo, Simonetta
    Criscitiello, Carmen
    Vigneri, Paolo
    Dei Tos, Angelo Paolo
    Maiorano, Eugenio
    Viale, Giuseppe
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
    Tolaney, Sara M.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Grischke, Eva-Maria
    Llombart-Cussac, Antonio
    Soliman, Hatem
    Wang, Hong
    Wijayawardana, Sameera
    Jansen, Valerie M.
    Litchfield, Lacey M.
    Sledge, George W., Jr.
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1500 - 1506
  • [10] SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA mutant tumors.
    Baselga, Jose
    Cortes, Javier
    De Laurentiis, Michelino
    Dieras, Veronique
    Harbeck, Nadia
    Im, Young-Hyuck
    Jacot, William
    Krop, Ian E.
    Verma, Sunil
    Wilson, Timothy R.
    Lin, Ray
    Schimmoller, Frauke
    Hsu, Jerry Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345